Company: BDRX
Filing Date: 2025-01-21
Form Type: 424B3
Source: 0001214659-25-000936
Chunk: 43

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-21
Form: 424B3
Chunk 43
---
 final version thereof from the Company. The Investor shall cooperate with the Company as reasonably requested
by the Company in connection with the preparation and filing of the Current Report and the Registration Statement with the SEC.

(b) . The Company shall take all such action, if any, as is reasonably necessary in order to obtain an exemption for or to register
or qualify (i) the issuance of the Commitment Shares, if applicable, and the sale of the Purchase Shares to the Investor under this Agreement
and (ii) any subsequent resale of any Commitment Shares and all Purchase Shares by the Investor, in each case, under applicable securities
or “Blue Sky” laws of the states of the United States in such states as is reasonably requested by the Investor from time
to time, and shall provide evidence of any such action so taken to the Investor; provided, however, that the Company shall not be obligated
to file any general consent to service of process or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction
in which it is not so qualified or to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise
so subject.

(c) .
The Company shall use its commercially reasonable efforts to promptly secure the listing of all of the Purchase Shares and Commitment
Shares, if any, to be issued to the Investor hereunder on the Principal Market (subject to official notice of issuance) and upon each
other national securities exchange or automated quotation system, if any, upon which the Depositary Shares are then listed, and shall
use commercially reasonable efforts to maintain, so long as any Depositary Shares shall be so listed, such listing of all such Securities
from time to time issuable hereunder. The Company shall use commercially reasonable efforts to maintain the listing of the Depositary
Shares on the Principal Market and shall comply in all respects with the Company’s reporting, filing and other obligations under
the bylaws or rules and regulations of the Principal Market. Neither the Company nor any of its Subsidiaries shall take any action that
would reasonably be expected to result in the delisting or suspension of the Depositary Shares on the Principal Market. The Company shall
promptly, and in no event later than four (4) Business Days after receipt, provide to the Investor copies of any notices it receives from
any Person regarding the continued eligibility of the Depositary Shares for listing on the Principal Market; provided, however, that the
Company shall not be required to provide the Investor